Amid al­ready plung­ing use of Mer­ck’s Covid-19 an­tivi­ral Lagevrio, preprint gives look in­to re­al world per­for­mance

One day af­ter the FDA grant­ed Pfiz­er’s Paxlovid emer­gency use au­tho­riza­tion in De­cem­ber, it did the same for Mer­ck’s Covid-19 an­tivi­ral mol­nupi­ravir, mar­ket­ed as Lagevrio …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.